Close Menu

NEW YORK (GenomeWeb) – Horizon Discovery Group reported on Monday that its total revenues as reported for the first half of 2018 more than doubled thanks to a significant contribution from its Dharmacon business and an increased reach into the US market.

For the six months ended June 30, the gene editing and gene modulation technologies company reported total revenues of £25.1 million ($33.0 million), up 107 percent from £12.1 million in the first half of 2017. On a constant currency basis, revenues rose 126 percent to £27.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.